22348-38-5

Basic information

• Product Name: cis-4-Methylamino-cyclohexanol
• Synonyms: cis-4-Methylamino-cyclohexanol;cis-4-(Methylamino)
• CAS NO: 22348-38-5
• Molecular Formula: C₇H₁₅NO
• Molecular Weight: 129.2001
• Mol File: 22348-38-5.mol
• Article Data: 1

Chemical Properties

• Boiling Point: 211.7°C at 760 mmHg
• Flash Point: 86.8°C
• Appearance: /
• Density: 0.97g/cm³
• Vapor Pressure: 0.0404mmHg at 25°C
• Refractive Index: 1.479
• Storage Temp.: 2-8°C
• CAS DataBase Reference: cis-4-Methylamino-cyclohexanol(CAS DataBase Reference)
• NIST Chemistry Reference: cis-4-Methylamino-cyclohexanol(22348-38-5)
• EPA Substance Registry System: cis-4-Methylamino-cyclohexanol(22348-38-5)

Safety Data

• Hazardous Substances Data: 22348-38-5(Hazardous Substances Data)

Usage

General Description

Cis-4-Methylamino-cyclohexanol, also known as dexoxadrol, is a chemical compound with a cyclohexane ring and an amino group attached to a methyl group in a cis configuration. It is a central nervous system depressant and a muscle relaxant that has sedative and analgesic effects. Dexoxadrol was previously used as a muscle relaxant and anesthetic agent, but its use has been discontinued due to its potential for abuse and addiction. It is classified as a Schedule I controlled substance in the United States, indicating that it has a high potential for abuse and no accepted medical use. Despite its potential as a therapeutic agent, its abuse liability has led to its limited use and availability.

InChI:InChI=1/C7H15NO/c1-8-6-2-4-7(9)5-3-6/h6-9H,2-5H2,1H3/t6-,7-

Upstream product

• 579-58-8 N-methyl-(4-acetamido)phenol 
• 167081-25-6 cis-(4-hydroxycyclohexyl)carbamic acid tert-butyl ester 

Downstream Products

• 561307-54-8 tert-butyl methyl(4-oxocyclohexyl)carbamate 
• 941598-28-3 cis-1-(methanesulphonyloxy)-4-(N-methanesulphonyl-N-methyl-amino)-cyclohexane 
• 798533-03-6 cis-1-(4-hydroxy-cyclohexyl)-3-[4-methoxy-7-(tetrahydro-pyran-4-yl)-benzothiazol-2-yl]-1-methyl-urea 

Relevant articles and documents

6-SUBSTITUTED ISOQUINOLINE DERIVATIVES

The present invention relates to 6-substituted isoquinoline derivatives having the general Formula I wherein X is O, S or NH; Y is OH or NH2; m is 0, 1 or 2; n is 0 or 1; o is 0 or 1; R1 is H, when Y is NH2; or R1 is H, (C1-4)alkyl or halogen, when Y is OH; R2 and R3 are independently H, (C1-4)alkyl or halogen; R4 is H or (C1-6)alkyl, optionally substituted with halogen, (C3-7)cycloalkyl, (C6-10)aryl or a saturated 5- or 6-membered heterocyclic ring comprising 1-3 heteroatoms independently selected from O, S and N, the (C6-10)aryl and heterocyclic ring being optionally substituted with (C1-4)alkyl, (C1-4)alkyloxy or halogen; R5 is H or (C1-4)alkyl; or a pharmaceutically acceptable salt thereof, with the proviso that the compounds of Formula I wherein X is O, Y is OH , n is 0 and m+o=2 are excluded, to pharmaceutical compositions comprising the same, as well as to the use of said 6-substituted isoquinoline derivatives for the preparation of a medicament for the treatment of ROCK-I related disorders such as glaucoma, hypertension and atherosclerosis.